scispace - formally typeset
G

Gianluca Pandolfo

Researcher at University of Messina

Publications -  81
Citations -  1570

Gianluca Pandolfo is an academic researcher from University of Messina. The author has contributed to research in topics: Anxiety & Anger. The author has an hindex of 19, co-authored 73 publications receiving 1195 citations.

Papers
More filters
Journal ArticleDOI

Workplace violence against healthcare professionals: A systematic review

TL;DR: The aim of this review is to examine the impact that exposure to workplace violence against healthcare professionals can produce, to improve healthcare professionals' knowledge about the consequences of workplace violence, and to guide future research in identifying strategies that could effectively reduce the incidence of workplaces violence.
Journal ArticleDOI

Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

TL;DR: Evidence is provided that aripiprazole augmentation of SRIs/clomipramine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.
Journal ArticleDOI

The Relationship between Alexithymia, Anxiety, Depression, and Internet Addiction Severity in a Sample of Italian High School Students

TL;DR: The findings showed that IA scores were associated with alexithymia scores, over and above the effect of negative emotions and age, and results showed that difficulty in identifying feelings was significantly associated with higher scores on IA severity.
Journal ArticleDOI

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

TL;DR: Evidence is provided that lamotrigine augmentation of SRI treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.
Journal ArticleDOI

Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

TL;DR: Evidence is provided that aripiprazole augmentation of clozapine treatment is well-tolerated and may be of benefit for patients who are partially responsive to clozAPine monotherapy; further double-blind, placebo-controlled trials in a larger number of patients are required to evaluate the therapeutic potential.